First-in-human Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Journal article published in 2017 by
Y. J. Bang,
G. Giaccone,
S. A. Im,
D. Y. Oh,
T. M. Bauer 
,
J. L. Nordstrom,
H. Li,
G. R. Chichili,
P. A. Moore,
S. Hong,
S. J. Stewart,
J. E. Baughman,
R. J. Lechleider,
H. A. Burris
,
J. L. Nordstrom,
H. Li,
G. R. Chichili,
P. A. Moore,
S. Hong,
S. J. Stewart,
J. E. Baughman,
R. J. Lechleider,
H. A. Burris
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 